National Semi /quotes/comstock/13*!nsm/quotes/nls/nsm (NSM 14.43, -0.04, -0.28%) is expected to report third-quarter earnings of 24 cents a share, according to a consensus survey by FactSet Research.
Vail Resorts Inc. /quotes/comstock/13*!mtn/quotes/nls/mtn (MTN 49.83, +0.19, +0.38%) is projected to post second-quarter earnings of $1.39 a share.
Pall Corp. /quotes/comstock/13*!pll/quotes/nls/pll (PLL 55.25, +0.02, +0.04%) is forecast to post second-quarter earnings of 57 cents a share.
Zumiez Inc. /quotes/comstock/15*!zumz/quotes/nls/zumz (ZUMZ 27.52, +0.43, +1.59%) is likely to report fourth-quarter earnings of 47 cents a share.
Aeropostale Inc. /quotes/comstock/13*!aro/quotes/nls/aro (ARO 24.91, -0.01, -0.03%) is expected to report fourth-quarter earnings of 97 cents a share.
Jamba Inc. /quotes/comstock/15*!jmba/quotes/nls/jmba (JMBA 2.25, -0.01, -0.44%) is projected to report a loss of 16 cents a share in the fourth quarter.
Smith & Wesson /quotes/comstock/15*!swhc/quotes/nls/swhc (SWHC 3.96, -0.01, -0.25%) is likely to post a third-quarter loss of a penny a share.
After Wednesday’s closing bell, the Food and Drug Administration said it approved Benlysta, a lupus drug from Human Genome Sciences /quotes/comstock/15*!hgsi/quotes/nls/hgsi (HGSI 25.68, +0.01, +0.04%) .
Human Genome, which developed Benlysta, will market the drug in the U.S. with GlaxoSmithKline PLC /quotes/comstock/13*!gsk/quotes/nls/gsk (GSK 39.49, +0.91, +2.36%) .
No comments:
Post a Comment